Delcath Systems, Inc.
NASDAQ:DCTH
10.5 (USD) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Delcath Systems, Inc. |
Symbool | DCTH |
Munteenheid | USD |
Prijs | 10.5 |
Beurswaarde | 294,008,400 |
Dividendpercentage | 0% |
52-weken bereik | 2.25 - 11.745 |
Industrie | Medical Devices |
Sector | Healthcare |
CEO | Mr. Gerard J. Michel MBA, MS |
Website | https://www.delcath.com |
An error occurred while fetching data.
Over Delcath Systems, Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)